Share Email Print

Proceedings Paper

Photodynamic therapy trials with lutetium texaphyrin (Lu-Tex) in patients with locally recurrent breast cancer
Author(s): Markus F. Renschler; Alan R. Yuen; Timothy J. Panella; Thomas Jeffery Wieman M.D.; Shona Dougherty; Laura Esserman; Masoud Panjehpour; Scott W. Taber M.D.; Victor H. Fingar; Elizabeth Lowe; Julie S. Engel; Bert Lum; Kathryn W. Woodburn; Wai-Fung Cheong; Richard A. Miller
Format Member Price Non-Member Price
PDF $14.40 $18.00
cover GOOD NEWS! Your organization subscribes to the SPIE Digital Library. You may be able to download this paper for free. Check Access

Paper Abstract

Photodynamic therapy (PDT) of locally recurrent breast cancer has been limited to treatment of small lesions because of non- selective necrosis of adjacent normal tissues in the treatment field. Lutetium Texaphyrin (PCI-0123, Lu-Tex) is a photosensitizer with improved tumor localization that is activated by 732 nm light, which can penetrate through larger tumors. We have evaluated Lu-Tex in a Phase I trial and in an ongoing Phase II trial in women with locally recurrent breast cancer with large tumors who have failed radiation therapy. Patients received Lu-Tex intravenously by rapid infusion 3 hours before illumination of cutaneous or subcutaneous lesions. In Phase I, Lu-Tex doses were escalated from 0.6 to 7.2 mg/kg in 7 cohorts. Sixteen patients with locally recurrent breast cancer lesions were treated. Dose limiting toxicities above 5.5 mg/kg were pain in the treatment field during therapy, and dysesthesias in light exposed areas. No necrosis of normal tissues in the treated field was noticed. Responses were observed in 60% of evaluable patients [n equals 15, 27% complete remission (CR), 33% partial remission (PR)], with 63% of lesions responding (n equals 73: 45% CR, 18% PR). In Phase II, 25 patients have been studied to date, receiving two treatments ranging from 1.0 to 3.0 mg/kg at a 21 day interval. Treatment fields up to 480 cm2 in size were treated successfully and activity has been observed. Patients have experienced pain at the treatment site but no tissue necrosis. These studies demonstrate the feasibility of Lu-Tex PDT to large chest wall areas in women who have failed radiation therapy for the treatment of locally recurrent breast cancer. Treatment conditions are currently being optimized in the ongoing Phase II trials.

Paper Details

Date Published: 19 May 1998
PDF: 5 pages
Proc. SPIE 3247, Optical Methods for Tumor Treatment and Detections: Mechanisms and Techniques in Photodynamic Therapy VII, (19 May 1998); doi: 10.1117/12.308147
Show Author Affiliations
Markus F. Renschler, Pharmacyclics, Inc. (United States)
Alan R. Yuen, Stanford Univ. (United States)
Timothy J. Panella, Thompson Cancer Survival Ctr. (United States)
Thomas Jeffery Wieman M.D., Univ. of Louisville (United States)
Shona Dougherty, Univ. of California/Los Angeles (United States)
Laura Esserman, Univ. of California/San Francisco (United States)
Masoud Panjehpour, Thompson Cancer Survival Ctr. (United States)
Scott W. Taber M.D., Univ. of Louisville (United States)
Victor H. Fingar, Univ. of Louisville (United States)
Elizabeth Lowe, Pharmacyclics, Inc. (United States)
Julie S. Engel, Pharmacyclics, Inc. (United States)
Bert Lum, Pharmacyclics, Inc. (United States)
Kathryn W. Woodburn, Pharmacyclics, Inc. (United States)
Wai-Fung Cheong, Pharmacyclics, Inc. (United States)
Richard A. Miller, Pharmacyclics, Inc. (United States)

Published in SPIE Proceedings Vol. 3247:
Optical Methods for Tumor Treatment and Detections: Mechanisms and Techniques in Photodynamic Therapy VII
Thomas J. Dougherty, Editor(s)

© SPIE. Terms of Use
Back to Top